Lysosomal storage disease gene therapy - Avigen
Latest Information Update: 07 Sep 2005
Price :
$50 *
At a glance
- Originator Avigen
- Developer Avigen; Johns Hopkins University
- Class Gene therapies
- Mechanism of Action Enzyme replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Fabry's disease; Gaucher's disease; Tay-Sachs disease
Most Recent Events
- 27 Jun 2005 Discontinued - Preclinical for Fabry's disease in USA (unspecified route)
- 27 Jun 2005 Discontinued - Preclinical for Gaucher's disease in USA (unspecified route)
- 27 Jun 2005 Discontinued - Preclinical for Tay-Sachs disease in USA (unspecified route)